Browsing Tag
Heinz Schwer
1 post
VERAXA Biotech seals $1.64bn SPAC merger to launch Nasdaq oncology powerhouse
Find out how VERAXA Biotech’s $1.64B Nasdaq listing is set to redefine cancer treatment with next-gen antibody therapies.